SCHEMBL4754584

SCHEMBL4754584

COc1cc(OC)c(SC(C)(C)CC(=O)O)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.40
CYP3A4 P08684 2/20 0.38
USP2 O75604 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
TP53 P04637 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
ACAT1 P24752 1/20 0.37
SOAT1 P35610 1/20 0.37
LMNA P02545 1/20 0.37
PTPN1 P18031 1/20 0.37
NPC1 O15118 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3867890 0.79 PTPN1 (0.41) HSD17B10CYP3A4USP2MAPK1SMN1; SMN2
SCHEMBL4697597 0.76 GAA (0.44) ALDH1A1
SCHEMBL727827 0.74 CA1 (0.43) HSD17B10MAPK1MAPTKDM4EALOX15
SCHEMBL1599400 0.71 HSD17B10 (0.56) HSD17B10CYP3A4USP2MAPK1SMN1; SMN2
SCHEMBL6593720 0.71 HTT (0.48) MAPK1MAPTKDM4ELMNAALDH1A1
SCHEMBL23162732 0.68 RXRA (0.42) MAPTKDM4ELMNAALDH1A1
SCHEMBL8746111 0.66 LDHA (0.46) SMN1; SMN2MAPTKDM4ELMNANPC1
SCHEMBL6512675 0.65 ALDH1A1 (0.50) HSD17B10CYP3A4USP2MAPK1SMN1; SMN2
SCHEMBL491024 0.65 POLB (0.50) HSD17B10CYP3A4USP2MAPK1SMN1; SMN2
SCHEMBL26195308 0.65 CYP3A4 (0.39) CYP3A4USP2MAPK1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109542-A4 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-03-26 EP disclosed
US-20050187222-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds NITROMED, INC. (US) 2005-08-25 US disclosed
US-6469065-B1 COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE NITROMED, INC. 2002-10-22 US disclosed
US-20020143007-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use GARVEY DAVID S (US) 2002-10-03 US disclosed
EP-1109542-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2001-06-27 EP disclosed
WO-2000012075-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187222-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds ADRB1, ADRB3, ADRA1D HSD17B10 2612/4885CYP3A4 461/4885USP2 2996/4885
US-20020143007-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use ADRB1, ADRB3, ADRA1D HSD17B10 2600/4885CYP3A4 504/4885USP2 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.